AN ASSESSMENT OF THE VALUE OF SERUM CA 125 MEASUREMENTS IN THE MANAGEMENT OF EPITHELIAL OVARIAN-CARCINOMA

被引:21
作者
GARD, GB
HOUGHTON, CRS
机构
[1] WESTMEAD HOSP,DEPT GYNAECOL ONCOL,WESTMEAD,NSW 2145,AUSTRALIA
[2] UNIV SYDNEY,DEPT OBSTET & GYNAECOL,SYDNEY,NSW 2006,AUSTRALIA
关键词
D O I
10.1006/gyno.1994.1135
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The records of 223 patients with epithelial ovarian carcinoma treated at Westmead Hospital and King George V Hospital between 1985 and 1991 were studied retrospectively to compare CA 125 levels with the clinical course of their disease. CA 125 parameters and established predictors of disease were compared using a Cox multivariate analysis to determine their relative prognostic value. The CA 125 trend was the most significant variable followed by the FIGO stage. The initial CA 125 level and nadir CA 125 level, although significant when considered alone, were not significant independent variables. The threshold for a raised CA 125 level was also considered and we propose that a lower level of 15 u/ml may be more useful as a cutoff when following patients with a known history of ovarian carcinoma. The rationale for this is that patients in our study with a nadir level in the intermediate range (15-35 u/ml) invariably developed recurrent disease. (C) 1994 Academic Press. Inc.
引用
收藏
页码:283 / 289
页数:7
相关论文
共 12 条
[1]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[2]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[3]  
CAIN JM, 1992, GYNECOL ONCOL, V46, P29
[4]   EXPERIENCES WITH CA-125, A TUMOR-MARKER FOR MALIGNANT EPITHELIAL OVARIAN-TUMORS [J].
CROMBACH, G ;
ZIPPEL, HH ;
WURZ, H .
GEBURTSHILFE UND FRAUENHEILKUNDE, 1985, 45 (04) :205-212
[5]   CA125 PARAMETERS IN SURVIVORS AND NONSURVIVORS WITH EPITHELIAL OVARIAN-CANCER [J].
CRUICKSHANK, DJ .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1991, 1 (06) :279-284
[6]   THE PROGNOSTIC-SIGNIFICANCE OF THE HALF-LIFE OF SERUM CA-125 IN PATIENTS RESPONDING TO CHEMOTHERAPY FOR EPITHELIAL OVARIAN-CARCINOMA [J].
HAWKINS, RE ;
ROBERTS, K ;
WILTSHAW, E ;
MUNDY, J ;
FRYATT, IJ ;
MCCREADY, VR .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1989, 96 (12) :1395-1399
[7]  
LAVIN PT, 1987, OBSTET GYNECOL, V69, P223
[8]   USE OF CA-125 TO MONITOR PATIENTS WITH OVARIAN EPITHELIAL CARCINOMAS [J].
PODCZASKI, E ;
WHITNEY, C ;
MANETTA, A ;
LARSON, JE ;
KIRK, J ;
STEVENS, CW ;
LYTER, J ;
MORTEL, R .
GYNECOLOGIC ONCOLOGY, 1989, 33 (02) :193-197
[9]   CA125 SERUM LEVELS AND SECONDARY LAPAROTOMY IN EPITHELIAL OVARIAN-TUMORS [J].
ROME, RM ;
KOH, H ;
FORTUNE, D ;
CAUCHI, M .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 1987, 27 (02) :142-145
[10]  
SCHILTHUIS MS, 1987, BRIT J OBSTET GYNAEC, V94, P202